Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges

Movement Disorders

Volumn 20, Issue 2, 2005, Pages 151-157

  Katzenschlager, Regina ^a,b,c   Hughes, Andrew ^d   Evans, Andrew ^a,b   Manson, Alice J ^e   Hoffmann, Marion ^d   Swinn, Lesley ^b   Watt, Hilary ^a   Bhatia, Kailash ^a   Quinn, Niall ^a   Lees, Andrew J ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c DANUBE HOSPITAL   (Austria)

^d AUSTIN HEALTH   (Australia)

^e SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Apomorphine; Dyskinesias; Parkinson's disease

Indexed keywords

ANTIDEPRESSANT AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SHORT ACTING DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DEPRESSION; DRUG DOSE REDUCTION; DRUG SENSITIZATION; DYSKINESIA; FEMALE; HUMAN; LEG EDEMA; MALE; MEDICAL RECORD; MONOTHERAPY; PANNICULITIS; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROVOCATION TEST; SCORING SYSTEM; SELF EVALUATION; SINGLE DRUG DOSE; SKIN MANIFESTATION; SKIN NODULE; STANDARDIZATION; TASK PERFORMANCE; VIDEORECORDING;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; APOMORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSKINESIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; LEVODOPA; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PAIN MEASUREMENT; PARKINSON DISEASE; PROSPECTIVE STUDIES; SELF ASSESSMENT (PSYCHOLOGY); STATISTICS, NONPARAMETRIC;

EID: 20144366287     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20276     Document Type: Article

References (50)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
2. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y, on behalf of the Parkinson's Disease Research Group of the United Kingdom. Ten-year follow-up of three different initial treatments in de-novo PD. Neurology 2001;57:1687-1694.
3. Cedarbaum J, Gandy SE, McDowell FH. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 1991;41:622-629.
4. Chase TN, Justin DO. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000; 47(Suppl. 1):S122-S130.
5. Jenner P. Factors influencing the onset and persistence of dyskinesias in MPTP-treated primates. Ann Neurol 2000;47(Suppl. 1): S90-S104.
6. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000;23(Suppl.):S109-S115.
7. Olanow CW, Schapira AHV, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 2000;23(Suppl.):S117-S126.
8. Sage JL, Schuh L, Heikkila RE, Duvoisin RC. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988;24:87-89.
9. Schuh LA, Bennett JP Jr. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993;43:1545-1550.
10. Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-163.
11. Obeso JA, Luquin MR, Martinez-Lage JM. Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease. Lancet 1986;i:467-470.
12. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
13. Chaudhuri KR, Critchley P, Abbott RJ, Pye IF, Millac PA. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease [letter]. Lancet 1988;2:1260.
14. Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol 1994;17: 243-259.
15. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993;8:165-170.
16. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long-term follow-up. J Neurol Neurosurg Psychiatry 1998;65:709-716.
17. Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. Adv Neurol 1993;60:656-659.
18. Steiger M, Quinn NP, Marsden CD. The clinical use of apomorphine in Parkinson's disease. J Neurol 1992;239:389-393.
19. Stibe CMH, Lees AJ, Kempster PA, Stem GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;I: 403-406.
20. Wenning GK, Böch S, Luginger E, Wagner M, Poewe W. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Adv Neurol 1999;80:545-548.
21. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-576.
22. Kanovsky P, Kubova D, Bares M, et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 2002;17: 188-191.
23. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002; 17:1235-1241.
24. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 2001;22:93-94.
25. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
26. Parkin SG, Gregory RP, Scott R, et al. Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: a case series of 115. Mov Disord 2002;17:682-692.
27. Fahn S, Elton RL and members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, editors. Recent developments in Parkinson's disease. London: MacMillan; 1987. p 153-163.
28. Lang AE, Fahn S. The dyskinesia subjective rating scale. Mov Disord 1999;14(Suppl. 1):79-80.
29. Melamed E, Olanow CW, Nutt JG, Lang AE. Dyskinesia assessment workshop: report from the working groups. Mov Disord 1999;14(Suppl. 1):69-73.
30. Durif F, Vidailhet M, Debilly B, Agid Y. Worsening of levodopa-induced dyskinesias by motor and mental tasks. Mov Disord 1999; 14:242-245.
31. Manson AJ, Brown P, O'Sullivan JD, Asselman P, Buckwell D, Lees AJ. An ambulatory dyskinesia monitor. J Neurol Neurosurg Psychiatry 2000;68:196-201.
32. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-394.
33. May PR, Lee MA, Bacon RC. Quantitative assessment of neuroleptic-induced extrapyramidal symptoms: clinical and nonclinical approaches. Clin Neuropharmacol 1983;6:S35-S51.
34. Acland KM, Churchyard A, Fletcher CL, Turner K, Lees AJ, Dowd PM. Panniculitis in association with apomorphine infusions. Br J Dermatol 1998;138:480-482.
35. Manson AJ, Hanagasi H, Turner K, et al. Intravenous apomorphine therapy in Parkinson's disease. Clinical and pharmacological observations. Brain 2001;124:331-340.
36. Engber TM, Susel Z, Juncos JL, Chase TN. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 1989;168:291-298.
37. Keijsers NL, Horstink MW, Gielen SC. Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks. Mov Disord 2003;18:70-80.
38. Manson AJ, Schrag A, Lees AJ. Low dose olanzapine for levodopa-induced dyskinesias in Parkinson's disease. Neurology 2000; 55:795-799.
39. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan. Mov Disord 2001; 16:642-650.
40. Turjanski N, Lees AJ, Brooks DJ. PET studies on striatal dopamine receptor binding in drug naive and L-dopa treated Parkinson's disease patients with and without dyskinesias. Neurology 1997;49: 717-723.
41. Piccini P, Weeks R, Brooks D. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997;42:720-726.
42. Benabid AL, Benazzouz A, Limousin P, et al. Dyskinesias and the subthalamic nucleus. Ann Neurol. 2000;47(Suppl. 1):S189-S192.
43. Deep Brain Stimulation for Parkinson's Disease Study Group. Deep brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001;345:956-963.
44. Fraix V, Pollak P, Van Blercom N, et al. Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease. Neurology 2000;55:1921-1923.
45. Kumar R, Lozano AM, Kim YJ, et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 1998;51:850-855.
46. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998;339:1105-1111.
47. Molinuevo JL, Valldeoriola F, Tolosa E, et al. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease. Arch Neurol 2000;57:983-988.
48. Romito LMA, Scerrati M, Contarino MF, Bentivoglio AR, Tonali P, Albanese A. Long-term follow up of subthalamic nucleus stimulation in Parkinson's disease. Neurology 2002;58:1546-1550.
49. Vingerhoets FJG, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson's disease. Two-year follow-up. Neurology 2002;58:396-401.
50. Bejjani BP, Arnulf I, Demeret S, et al. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? Ann Neurol 2000;47:655-658.